- RCEP negotiators must fix the damaging provisions that remain a threat to public health
- Escaping Big Pharma’s Pricing With Patent-Free Drugs
- An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali
- COLD RECEPTION TO RCEP AS PEOPLE’S RESISTANCE CONSOLIDATES
- Company sues Ukraine in bid to corner hepatitis C drug market
Category Archives: Hepatitis C
(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading
A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has … Continue reading
By Shreerupa Mitra-Jha, Firstpost | July 8, 2016 The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of … Continue reading
By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading
Source: ThePharmaLetter | May 10, 2016 The Russian government has decided to postpone the introduction of a controversial scheme for the compulsory licensing of drugs imported into Russia, as proposed by some local drugmakers, reports The Pharma Letter’s local correspondent.
By Deena Beasley, The Reuters | May 10, 2016 India has reversed course and granted approval to Gilead Sciences Inc’s patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable … Continue reading